by Raynovich Rod | Jul 5, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-4 JY 12…Some biotech strength in usual suspects but exciting news drives smaller more speculative stocks. Recursion pharmaceuticals (RXRX) up 78% on $50M Nvidia drug discovery deal. As rumored AI meets biotech.Trading rally for sure as more AI plays...
by Raynovich Rod | Jun 26, 2023 | 2025 Rayno Biopharmaceuticals Portfolio
Update-2 Flashback from 1/19 and 2018 Performance. Big winner in 2018 was MRK up 33% to $76.41 but 2018 was a bad year with the XBI down 15% to $71.75. But Regeneron was a bargain on 1/19 at $373. Update-1 6/27…A bad day for Biotech but a nice rally day for Tech...
by Raynovich Rod | Jun 21, 2023 | Biopharmaceuticals
Healthcare Stocks Lag but Trading Action is Picking up in Biotech Large Cap Biopharma are core holdings: ABBV, LLY, MRK, REGN, VRTX etc. Healthcare is a laggard with XLV down YTD but UNH is still a core position. Lack of Momentum in SMID caps-XBI is still the key...
by Raynovich Rod | Jun 12, 2023 | 2024-25 Life Science Portfolios, Macro
Update-2 6/18…11 a EDT, Medtech Rally: FSMEX , IHI, ABT, BSX etc. Update-1 2P EDT 6/14…FED day brings volatility and easing of momentum. Don’t fight the tape with small caps weak. XBI is down 2%, Russell 2000 is down 1.65%. We started selling and...
by Raynovich Rod | Jun 5, 2023 | 2024-25 Life Science Portfolios, Biopharmaceuticals
FOCUS on SMID biotech stocks. Update-2 ..more rotation out of tech and large cap biopharma and healthcare (UNH, XLV still weak) into value and cyclicals; energy very strong we’ll see. We still prefer SMID in biotech per our Life Science Portfolio. Today XBI was...
by Raynovich Rod | May 30, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update -1 3/31 2P EDT. With momentum easing in Chip and IT trades this can be a good entry point for large cap biopharma stocks ahead of ASCO June 2: GILD, MRK so stay tuned. Also for value “bottom fishers” Pfizer offers a good yield of 4.4% with a FWD...
by Raynovich Rod | May 22, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 5/27/23… Not a great week for healthcare stocks or anything other than IT and the QQQ up 3.59%. S&P 500 Healthcare down 2.93%, Materials down 3.14%, Staples down 3.21%. No debt ceiling deal, recession watch is on. So Karen Firestone, former manager...
by Raynovich Rod | May 15, 2023 | 2024-25 Life Science Portfolios
Update-2…May 19 1015a in early trading, stocks are opening on the green side. Biopharma stocks are trying to firm up after a spate of weakness from the FTC action on the AMGN/Horizon deal: ABBV, GILD, LLY, REGN, RHHBY MRK, VRTX. Update-1 May 17 …Broad...
by Raynovich Rod | May 8, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 5/9/23 Biotech holding up nicely. XBI up 1.48% to $86 handle. CRSP up 14% to $64 handle, NTLA up 2%. GILD in buying range under $80 with 3.76% dividend, FWD PE of 10.9 and strong position in HIV/Aids, viral hepatitis, coronaviruses and emerging portfolio in...
by Raynovich Rod | May 1, 2023 | 2024-25 Life Science Portfolios, Macro
Update-2 5/5….11a EDT Biotech rally continues with strength in SMID stocks: up 1.9% to $85 handle. Gene therapy stocks strong: CRSP EDIT NTLA. IWM up 1.83%to 1750. Spec small caps up big: Acumen (ABOS) up 30% on AD research , VCYT ARKG flat at $29 level. Mid...
